Drug Profile
Research programme: cancer therapeutics - Handok Inc.
Alternative Names: HL 1172; HL 5171; HL-3171Latest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator Handok Pharmaceuticals
- Developer Handok Inc
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2018 No recent reports of development identified for research development in Cancer in South Korea
- 24 May 2016 Early research is ongoing in South Korea
- 21 Aug 2014 Early research is ongoing in South Korea